Intermediate dose pre-operative irradiation for carcinoma of the rectum

Takashi Uno, Shigeo Yasuda, Takashi Aruga, Koichi Isobe, Namio Machida, Hiroyuki Kawakami, Tetsuya Kawata, Masaru Miyazaki, Hisao Ito

Research output: Contribution to journalArticle

Abstract

Background: To assess the locoregional control, survival and toxicities of combined intermediate-dose preoperative irradiation and surgery for rectal cancer patients. Materials and Methods: Forty-two patients with adenocarcinoma of the rectum underwent intermediate-dose pre-operative radiotherapy. The median age was 58 years, the prescribed dose was 30.6 Gy to the whole pelvis, while a boost of 4x3 Gy to the primary tumor was added. The calculated linear-quadratic dose was 52 Gy. Results: Failure as a first site was pelvic in 2 and distant in 11. The crude pelvic failure rate was 9.5%. The 3- and 5-year overall survival was 75% and 63%, respectively. Pre-operative radiotherapy was well-tolerated by all. No anastomotic breakdown was seen. Nor was any death attributable to any adverse effects of the treatment. Conclusion: The present results suggested that pre-operative intermediate-dose radiotherapy is effective in preventing pelvic recurrence in rectal cancer patients with acceptable toxicities.

Original languageEnglish
Pages (from-to)3013-3017
Number of pages5
JournalAnticancer research
Volume22
Issue number5
Publication statusPublished - 2002 Sep 1

Keywords

  • Biologically effective dose
  • Intermediate dose
  • Pre-operative radiotherapy
  • Rectal carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Intermediate dose pre-operative irradiation for carcinoma of the rectum'. Together they form a unique fingerprint.

  • Cite this

    Uno, T., Yasuda, S., Aruga, T., Isobe, K., Machida, N., Kawakami, H., Kawata, T., Miyazaki, M., & Ito, H. (2002). Intermediate dose pre-operative irradiation for carcinoma of the rectum. Anticancer research, 22(5), 3013-3017.